Search PubMed⌕ Search

Biomedical subjects

C M Clancy

Publications and source records attributed to C M Clancy.

58 records · Page 4Linked to original sources

Making capitated Medicare work for women: policy and research challenges.

Growth in capitated Medicare has special ramifications for older women who comprise the majority of Medicare beneficiaries. Older women are more likely than men to have chronic conditions that lead to illness and disability, and they often have fewer financial and social resources to cope with these problems. Gender differences in health status have a number of important implications for the financing and delivery of care for older women under both traditional fee-for-service Medicare and capitation. The utilization of effective preventive interventions, new therapeutic interventions for the management of common chronic disorders, and more cost-effective models of chronic disease management could potentially extend the active life expectancy of older women. However, there are financial and delivery system barriers to achieving these objectives. Traditional FFS Medicare has gaps in coverage of care for chronic illness and disability that disproportionately impact women. Managed care potentially offers flexibility to allocate resources creatively, to develop new models of care, and offer enhanced benefits with lower out-of-pocket costs. However, challenges to realizing this potential under Medicare managed care with unique implications for older women include: possible gender bias in capitation payments, risk selection, inadequacy of risk adjustment models, benefit and market instability, and disenrollment patterns.

Aged↗

Drug coverage decisions: the role of dollars and values.

Given the increasing costs of pharmaceuticals today, it is important to understand how pharmacy benefits decisions are made and the role of cost and values in these decisions. This study examines what coverage decisions insurers make and the information and processes used in making these decisions. Fifty-three organizations, differing in size, tax status, and region, were asked about their policies for four new and controversial drugs: Viagra, Enbrel, Zyban, and Celebrex. Enbrel and Celebrex were much more likely to be covered than Viagra and Zyban. In addition, coverage of Enbrel and Celebrex was limited through strategies such as prior authorization, to encourage medically appropriate use of these agents, whereas coverage of Viagra and Zyban was limited predominantly through generalized exclusion or through restrictions on quantity or duration of use. Value judgments, rather than cost, seem to play a central, though largely unspoken, role in these coverage decisions.

Anti-Inflammatory Agents, Non-Steroidal↗

Health care reform, primary care, and the need for research.

Health care reform proposals that seek to increase access for almost 40 million uninsured Americans will require an expansion of primary care. Simply expanding available primary care services is likely to be prohibitively expensive. Developing a rational and efficient strategy for the provision of primary care to all Americans will require understanding of the relationships among primary care and access, costs, and quality--relationships that are often obscured by the complexity of the US health care system. Those relationships are examined to identify some key areas of research needed to inform policy development and improve primary care services. Despite significant gaps in our knowledge, the evidence strongly suggests that restructuring and strengthening the role of primary care practitioners in the health care system will facilitate access to affordable, high-quality health care for all Americans.

Health Care Costs↗